

# Maximilian F Konig

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/21824/maximilian-f-konig-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

52  
papers

1,157  
citations

16  
h-index

33  
g-index

60  
ext. papers

1,705  
ext. citations

10.4  
avg, IF

5.01  
L-index

#	Paper	IF	Citations
52	Aggregatibacter actinomycetemcomitans-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis. <i>Science Translational Medicine</i> , <b>2016</b> , 8, 369ra176	17.5	289
51	A Critical Reappraisal of Neutrophil Extracellular Traps and NETosis Mimics Based on Differential Requirements for Protein Citrullination. <i>Frontiers in Immunology</i> , <b>2016</b> , 7, 461	8.4	146
50	Defining the role of Porphyromonas gingivalis peptidylarginine deiminase (PPAD) in rheumatoid arthritis through the study of PPAD biology. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 2054-61	2.4	73
49	Preventing cytokine storm syndrome in COVID-19 using $\beta_1$ adrenergic receptor antagonists. <i>Journal of Clinical Investigation</i> , <b>2020</b> , 130, 3345-3347	15.9	69
48	Targeting a neoantigen derived from a common mutation. <i>Science</i> , <b>2021</b> , 371,	33.3	68
47	Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 1386-1388	2.4	56
46	Bispecific antibodies targeting mutant neoantigens. <i>Science Immunology</i> , <b>2021</b> , 6,	2.8	42
45	Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 659-666	5.1	40
44	Antibodies to native and citrullinated RA33 (hnRNP A2/B1) challenge citrullination as the inciting principle underlying loss of tolerance in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 2022-2028	2.4	36
43	: hydroxychloroquine, COVID-19 and the role of the rheumatologist. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 734-736	2.4	32
42	The microbiome in autoimmune rheumatic disease. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2020</b> , 34, 101473	5.3	29
41	Rheumatoid Arthritis-Associated Autoimmunity Due to and Its Resolution With Antibiotic Therapy. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2352	8.4	24
40	Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 2696	8.4	22
39	Sarcoidosis and autoimmune diseases: differences, similarities and overlaps. <i>Current Opinion in Pulmonary Medicine</i> , <b>2018</b> , 24, 504-512	3	22
38	SARS-CoV-2 Infection and COVID-19 Outcomes in Rheumatic Disease: A Systematic Literature Review And Meta-Analysis. <i>Arthritis and Rheumatology</i> , <b>2021</b> ,	9.5	20
37	Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation. <i>Expert Review of Clinical Immunology</i> , <b>2020</b> , 16, 1185-1204	5.1	18
36	Targeting loss of heterozygosity for cancer-specific immunotherapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	14

35	The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 637647	4.9	12
34	Elevated Erythrocyte Sedimentation Rate Is Predictive of Interstitial Lung Disease and Mortality in Dermatomyositis: a Korean Retrospective Cohort Study. <i>Journal of Korean Medical Science</i> , <b>2016</b> , 31, 389-96	4.7	12
33	Smoking is not linked to the development of anti-peptidylarginine deiminase 4 autoantibodies in rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , <b>2018</b> , 20, 59	5.7	11
32	Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases. <i>Lancet Rheumatology</i> , <i>The</i> , <b>2021</b> , 3, e707-e714	14.2	11
31	Targeting the catecholamine-cytokine axis to prevent SARS-CoV-2 cytokine storm syndrome		10
30	TCR $\beta$ -chain-directed bispecific antibodies for the treatment of T cell cancers. <i>Science Translational Medicine</i> , <b>2021</b> , 13,	17.5	10
29	Targeting public neoantigens for cancer immunotherapy. <i>Nature Cancer</i> , <b>2021</b> , 2, 487-497	15.4	10
28	Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 141-148	2.4	10
27	PPAD is not targeted as a citrullinated protein in rheumatoid arthritis, but remains a candidate for inducing autoimmunity. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, e8	2.4	8
26	Response to comment on "LPS-induced hypercitrullination links periodontal infection to autoimmunity in rheumatoid arthritis". <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	7
25	Association of Higher Hydroxychloroquine Blood Levels With Reduced Thrombosis Risk in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 997-1004	9.5	7
24	Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection. <i>ELife</i> , <b>2021</b> , 10,	8.9	7
23	Insights into the significance of peptidylarginine deiminase 4 and antibodies against citrullinated antigens in the absence of "true ACPAs" in an experimental model of arthritis: comment on the article by Shelef et al. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 2642-4	9.5	6
22	Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens. <i>Nature Communications</i> , <b>2021</b> , 12, 5271	17.4	5
21	Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine	2.4	4
20	Exposure to before Symptom Onset and the Risk of Evolving to Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	3
19	Acute Bilateral Pseudogout of the Temporomandibular Joint. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1159-5	9.5	3
18	The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19 <b>2021</b> ,		3

17	A Pharmacokinetics-Informed Approach to Navigating Hydroxychloroquine Shortages in Patients With Rheumatic Disease During the COVID-19 Pandemic. <i>ACR Open Rheumatology</i> , <b>2020</b> , 2, 491-495	3.5	3
16	Inflammatory arthritis in patients with COVID-19. <i>Translational Research</i> , <b>2021</b> , 232, 49-59	11	3
15	Associations of Antibodies Targeting Periodontal Pathogens With Subclinical Coronary, Carotid, and Peripheral Arterial Atherosclerosis in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2021</b> , 73, 568-575	9.5	3
14	Citrullination of a phage-displayed human peptidome library reveals the fine specificities of rheumatoid arthritis-associated autoantibodies. <i>EBioMedicine</i> , <b>2021</b> , 71, 103506	8.8	3
13	Author response: Alpha-1 adrenergic receptor antagonists to prevent hyperinflammation and death from lower respiratory tract infection <b>2021</b> ,		2
12	Subscapular bursitis as a rare manifestation of dermatomyositis: a case report. <i>European Journal of Rheumatology</i> , <b>2015</b> , 2, 80-82	1.7	1
11	Response to: Correspondence on T hydroxychloroquine, COVID-19 and the role of the rheumatologist Tby Graef Tby Lo. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	1
10	COVID-19 outcomes among hospitalized men with or without exposure to alpha-1-adrenergic receptor blocking agents		1
9	More on CD19-CAR T Cells in Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, e67	59.2	0
8	Ten Rules for Conducting Retrospective Pharmacoepidemiological Analyses: Example COVID-19 Study. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 700776	5.6	0
7	The impact of COVID-19 on rheumatology training-results from the COVID-19 Global Rheumatology Alliance trainee survey.. <i>Rheumatology Advances in Practice</i> , <b>2022</b> , 6, rkac001	1.1	0
6	Digit Ulcerations in a Young Woman. <i>JAMA - Journal of the American Medical Association</i> , <b>2020</b> , 324, 385-386		0
5	FRI0356 Antibodies to Perforin-Induced Citrullinated Hnrnp A1 Are Associated with Erosive Rheumatoid Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 516.1-516	2.4	
4	Response to: Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis Tby Singer. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> ,	2.4	
3	Inside and Out. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1753-1760	59.2	
2	Respiratory Distress and Nephropathy in a Young Male With Small-Joint Polyarthritis. <i>Arthritis Care and Research</i> , <b>2016</b> , 68, 1173-9	4.7	
1	Inpatient Administration of Alpha-1-Adrenergic Receptor Blocking Agents Reduces Mortality in Male COVID-19 Patients.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 849222	4.9	